Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Tractor Supply Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while Tractor Supply Co trades at $36.39 (market cap $18.39B). The key difference: Tractor Supply Co is far larger — about 3.6× ACADIA Pharmaceuticals Inc.'s market cap, and Tractor Supply Co pays a 2.72% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TSCO | |
|---|---|---|
Market Cap | $5.07B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $62.65 |
52-Week Low | $20.06 | $29.14 |
Enterprise Value | $4.19B | $24.70B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Tractor Supply (TSCO) trades at $36.24, up 4.68% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported $15.52B in 2025 revenue with a net margin of 6.42%, though recent quarters saw EPS misses. Valuation metrics include a P/E of 18.38 and ROE of 39.51%, indicating strong profitability but high price-to-book at 6.99. Recent news highlights CEO share purchases and dividend declarations amid a 2026 outlook cut due to weak demand.
The stock presents a cautious opportunity with solid fundamentals offset by near-term headwinds. Upside potential exists from digital growth and pet initiatives, but risks include discretionary spending pressure and cost inflation. Analysts are divided, with a $36.29 price target suggesting limited upside from current levels, requiring careful monitoring of holiday sales and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
